In fact, the problems of treating cardiovascular diseases based on MSCs have been clearly described previously,328 including (1) lack of assessment of the potential of MSCs transdifferentiation into functional cardiac and endothelial cells in vitro,329 (2) uncontrolled differentiation of MSCs into undesirable cell types after administration,330 and (3) indistinguishable nature MSCs obtained from several sources, with diverse levels of differentiation potential.331 thus, the use of MSC-based therapy in cardiovascular diseases still at the initial stage|early stage|with recent infection}, and http://www.fbevalvolari.com/2021/08/20/pcb-designdevelop-routing-di-circuiti-stampati/ can bring potential benefits to patients.